2. UroToday Home
  3. Video Lectures

Advanced Bladder Cancer Videos

Muscle-Invasive Bladder Cancer in Non-Curative Patients: A Study on Survival and Palliative Care Needs - Beyond the Abstract
November 21, 2024
Details
Five Things Urologists Need to Know About Bladder and Kidney Cancer in 2025 "Presentation" - Gautam Jayram
November 19, 2024
Details
Study Finds Whole Pelvis Radiotherapy Superior to Bladder-Only in MIBC Treatment - Gautier Marcq
November 13, 2024
Details
Innovative Therapies in GU Cancers: Promising Targets in Urothelial and Kidney Cancer - Jonathan Rosenberg
November 7, 2024
Details
Quality of life after Trimodality Therapy - Kimberley Mak
November 6, 2024
Details
5-Year Survival Outcomes in Cisplatin-Ineligible Patients from EV-103 - Jonathan Rosenberg
November 4, 2024
Details
NIAGARA Trial Shows Durvalumab Plus Chemotherapy Improves Survival in Muscle-Invasive Bladder Cancer - Thomas Powles
November 4, 2024
Details
Nectin-4 Expression Not Predictive of Response in Enfortumab Vedotin Therapy - Thomas Powles
November 4, 2024
Details
Addressing Cognitive Decline in Bladder Cancer Patients Through Prehab and Rehab - Sarah Psutka
October 25, 2024
Details
Bridging Evidence to Practice: Bladder Cancer Therapy Guidelines and Global Implementation - Andrea Apolo
October 23, 2024
Details
SWOG Trial On Standard vs Extended Lymphadenectomy in Muscle Invasive Bladder Cancer - Seth Lerner
October 15, 2024
Details
EV-302 Trial Analysis Evaluating Nectin-4 in Urothelial Cancer - Thomas Powles
October 11, 2024
Details
NIAGARA Trial: Chemo Plus Durvalumab Improves Survival in Muscle-Invasive Bladder Cancer - Thomas Powles
October 11, 2024
Details
Variant Histology Bladder Cancer Challenges and Future Directions - Syed Hussain
October 7, 2024
Details
Bladder Cancer Research Explores Fecal Transplants and Nutritional Strategies - Laura Bukavina
October 5, 2024
Details
Highlights in Non-Prostate GU Oncology from ESMO 2024 - Ignacio Duran
October 4, 2024
Details
Enfortumab Vedotin and Stereotactic Radiation Tested Before Surgery in Muscle-Invasive Bladder Cancer in STAR-EV Trial - Tian Zhang
October 2, 2024
Details
Event-Free Survival as Surrogate Endpoint in Muscle Invasive Bladder Cancer Research - Cora Sternberg
October 1, 2024
Details
Bladder Cancer Breakthroughs in SunRISe-1, AMBASSADOR, and VOLGA Trials - Maria De Santis
September 21, 2024
Details
SunRISe-4 Trial Explores TAR-200 and Cetrelimab Combination for Bladder Cancer Treatment - Andrea Necchi
September 16, 2024
Details
Disitamab Vedotin: Promising HER2-Targeted Therapy for Urothelial Cancer - Matthew Galsky
September 15, 2024
Details
AMBASSADOR Trial: Extended Follow-up on Adjuvant Pembrolizumab in Bladder Cancer - Andrea Apolo
September 15, 2024
Details
Trimodal Therapy in Urothelial vs Non-Urothelial Bladder Cancer - Mario de Angelis
July 22, 2024
Details
The Best of ASCO 2024 in Advanced Bladder Cancer - Shilpa Gupta
July 3, 2024
Details
Small Cell Neuroendocrine Carcinoma of Urinary Tract: Relapse Factors & Treatment - Omar Alhalabi
July 2, 2024
Details
dMMR and MSI-H in Urothelial Carcinoma: Prevalence and Treatment Implications - Elias Chandran
June 29, 2024
Details
Bladder-Sparing Chemoradiation for Localized Bladder Cancer: Addressing the Unmet Need - Brent Rose
June 18, 2024
Details
EV-302 Subgroup Analysis: Improved Outcomes for Cisplatin-Ineligible Advanced Urothelial Cancer Patients - Michiel Van der Heijden
June 12, 2024
Details
SunRISe-2 Trial: TAR-200 and Cetrelimab vs. Chemoradiotherapy for Muscle-Invasive Bladder Cancer - Stephen Williams
June 8, 2024
Details
Antibody-Drug Conjugates in Advanced Urothelial Cancer: Current Landscape and Future Directions - Matthew Galsky & Neal Shore
June 6, 2024
Details
Innovative Trials Highlight Progress in Treating Urothelial Carcinoma at AUA 2024 - Karim Chamie
May 24, 2024
Details
AUA 2024 Urothelial Carcinoma Highlights - Woodson Smelser
May 23, 2024
Details
Pembrolizumab + Chemoradiation vs. Trimodality Therapy for Muscle-Invasive Bladder Cancer: The KEYNOTE-992 Trial - Neal Shore
May 23, 2024
Details
Immunotherapy Advancements in Bladder Cancer: Clinical Trials, Early Intervention, and Toxicity Management - Matt Galsky & Neal Shore
May 21, 2024
Details
Balancing Bladder Preservation with Effective Treatment in Cancer Care - Petros Grivas
May 17, 2024
Details
Treatment Options for Advanced Urothelial Cancer Post-EV-302 - Shilpa Gupta & Karima Oualla
May 16, 2024
Details
Stool Microbiome Signature Predicts Response to Neoadjuvant Pembrolizumab in Muscle-Invasive Bladder Cancer - Filippo Pederzoli & Massimo Alfano
May 8, 2024
Details
EV-302 Subgroup Analyses: Enfortumab Vedotin + Pembrolizumab Effective Across Patient Subsets in Metastatic Urothelial Cancer - Jonathan Rosenberg
May 6, 2024
Details
Navigating the Shift to Enfortumab Vedotin and Pembrolizumab in Advanced Urothelial Cancer: Key Considerations for Clinicians - Cora Sternberg
April 24, 2024
Details
Preclinical Study Evaluates Enfortumab Vedotin and Sacituzumab Govitecan with Radiation for Bladder Cancer - Kent Mouw
April 23, 2024
Details
Genomic Tumor Correlates of Response to Trimodal Therapy for Muscle-Invasive Bladder Cancer - Sophia Kamran
April 22, 2024
Details
Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer, Journal Club - Rashid Sayyid & Zachary Klaassen
March 19, 2024
Details
Erdafitinib or Chemotherapy in Advanced or Metastatic Urothelial Carcinoma - Arlene Siefker-Radtke
March 6, 2024
Details
EV-302: Enfortumab Vedotin + Pembrolizumab Outperforms Chemo in Untreated Advanced Urothelial Cancer - Michiel Simon Van der Heijden
March 4, 2024
Details
Adjuvant Pembrolizumab in Urothelial Carcinoma: AMBASSADOR Study Findings - Andrea Apolo
March 1, 2024
Details
Outcomes of Enfortumab Vedotin After Platinum and Avelumab in Bladder Cancer - Amanda Nizam
March 1, 2024
Details
Combination Maintenance Therapy for Advanced Bladder Cancer Explored in MAIN-CAV Study - Shilpa Gupta
February 28, 2024
Details
Utilization of Neoadjuvant Chemo Before Cystectomy - Hiten Patel
January 29, 2024
Details
International Panel Defines Endpoints and Control Arms for Trials in Locally Advanced and Metastatic Bladder Cancer, Journal Club - Rashid Sayyid & Zachary Klaassen
January 3, 2024
Details
Multi-Disciplinary Panel Defines Clinical Trial Framework for Muscle-Invasive Bladder Cancer, Journal Club - Rashid Sayyid & Zachary Klaassen
December 21, 2023
Details
Gemcitabine, Cisplatin and Immunotherapy: A Promising Mix for Advanced Bladder Cancer - Guru Sonpavde & Matthew Galsky
November 21, 2023
Details
Novel Antibody-Drug Conjugate Combination Yields High Response in Advanced Bladder Cancer - Guru Sonpavde & Bradley McGregor
November 21, 2023
Details
For Bladder Cancer Patients, New Hope From Immunotherapy Innovations from ESMO 2023 - Petros Grivas
November 14, 2023
Details
The EV-302 Study and the Implications for Metastatic Bladder Cancer Care - Cora Sternberg
November 13, 2023
Details
EV-103 Study Update: Impressive Four-Year Data on Enfortumab Vedotin and Pembrolizumab Combination in Urothelial Cancer - Shilpa Gupta
July 10, 2023
Details
Outcomes with Immune Checkpoint Inhibitors in Patients with MTAP Alterations in Advanced Urothelial Carcinoma - Rafee Talukder
July 3, 2023
Details
A Breakthrough in Urothelial Cancer Treatment: Enfortumab Vedotin Combination Therapy - Expert Insights and Impressive Response Rates - Jonathan E. Rosenberg
June 23, 2023
Details
Radical Cystectomy Versus Trimodality Therapy for Muscle-Invasive Bladder Cancer: A Multi-Institutional Propensity Score Matched and Weighted Analysis - Jason Efstathiou & Alexandre Zlotta
June 22, 2023
Details
New Prognostic Model in Patients with Advanced Urothelial Carcinoma Treated with Second-Line Immune Checkpoint Inhibitors - Beyond the Abstract
May 31, 2023
Details
The San Raffaele Urologic Oncology Retreat: Examples of ECOG-ACRIN Research Initiatives - Petros Grivas
May 31, 2023
Details
The TAR-200 Device in Muscle-Invasive Bladder Cancer: Safety, Efficacy, and Future Prospects - Mark D. Tyson, II
May 23, 2023
Details
Addressing Challenges in Bladder Cancer Surgery: Enhancing Patient Outcomes and Preparing for Recovery - Sarah Psutka
May 23, 2023
Details
Full Data Analysis of the Biology and Performance of Pre- and Post-Pembrolizumab VI-RADS for Predicting Pathological Response in MIBC: Insights from a Comprehensive Clinical Trials Pipeline - Andrea Necchi
May 17, 2023
Details
Pros and Cons of Organ-Sparing Cystectomy in Bladder Cancer Patients: Balancing Oncologic and Functional Outcomes - Param Mariappan & Maria Carmen Mir
May 12, 2023
Details
Long-Term Results of the IMvigor130 Study: Atezolizumab with or without Chemotherapy in Metastatic Urothelial Cancer – Matthew Galsky
April 24, 2023
Details
Neoadjuvant Chemo-Immunotherapy Affect on Downstaging in Cisplatin-Eligible and Ineligible MIBC Patients Prior to Definitive Surgery, HCRN GU14-188: Phase Ib/II Study - Jason Brown
April 20, 2023
Details
Gemcitabine, Cisplatin, and Nivolumab with Selective Bladder Sparing in MIBC: Co-Primary Endpoint Analysis of HCRN GU 16-256 Phase II Trial - Matthew Galsky
April 5, 2023
Details
Exploring Genetic Biomarkers of Response to Enfortumab Vedotin in Advanced Urothelial Carcinoma: Analysis of UNITE Dataset - Tanya Jindal & Vadim Koshkin
April 5, 2023
Details
Assessing the Impact of Enfortumab Vedotin and Pembrolizumab on QoL and Symptom Management in Urothelial Carcinoma: EV-103 Cohort K Study Results - Matthew Milowsky
April 5, 2023
Details
The Phase 1B NABUCCO Trial: The Use of Either High or Low-Dose Preoperative Ipilimumab plus Nivolumab in Patients with Stage III Urothelial Cancer – Michiel Van Der Heijden
March 28, 2023
Details
Extended Follow-Up Results of the CheckMate 274 Trial: Adjuvant Nivolumab for Resected Muscle-Invasive Urothelial Carcinoma - Matthew Galsky
March 27, 2023
Details
Long-Term Follow-up from the JAVELIN Bladder 100 Trial - Srikala Sridhar
March 24, 2023
Details
The Association Between FGFR3 Alterations and Response to Platinum-based Chemotherapy in Locally Advanced and Metastatic Urothelial Carcinoma - Gopa Iyer
March 21, 2023
Details
The Use of Biomarkers in the Adjuvant Setting to Understand the Effect of Nivolumab in the Checkmate 274 Study - Andrea Necchi
March 16, 2023
Details
Results from the Phase 1b/2 FIDES-02 Study: Derazantinib for Metastatic Bladder Cancer with Activating FGFR1/2/3 Genetic Aberrations - Andrea Necchi
March 16, 2023
Details
Extended Follow-Up Results CheckMate 274 Trial and Results of Pembrolizumab Monotherapy in BCG-Unresponsive HR NMIBC: Findings from Cohort B of the KEYNOTE-057 Trial - Michiel Van der Heijden
March 28, 2023
Details
TROPHY-U-01 Cohort 3 Primary Analysis Sacituzumab Govitecan in Combination with Pembrolizumab in Patients with Metastatic Urothelial Cancer That Progressed after Platinum-Based Therapy - Petros Grivas
February 23, 2023
Details
The Future of Immune Checkpoint Inhibitors in the First-Line Treatment of Metastatic Urothelial Carcinoma - Andrea Apolo
February 23, 2023
Details
The Role of Avelumab Switch Maintenance Immunotherapy in the Front-Line Space of Patients with Advanced Urothelial Cancer - Srikala Sridhar
March 7, 2023
Details
From Dismal to Promising: Discoveries Transforming Treatment Options for Advanced Urothelial Carcinoma - Shilpa Gupta
January 27, 2023
Details
Results of Cohort K of the EV-103 Trial EV Monotherapy or in Combination With Pembro in Previously Untreated Cisplatin-Ineligible Patients With Locally Advanced or Metastatic Urothelial Cancer - Guru Sonpavde
December 12, 2022
Details
Long-Term Outcomes in EV-301, Enfortumab Vedotin Versus Chemotherapy in Patients With Previously Treated Advanced Urothelial Carcinoma - Jonathan Rosenberg
December 6, 2022
Details
EV-201 Enfortumab Vedotin After PD-1 or PD-L1 Inhibitors in Cisplatin-Ineligible Patients with Advanced Urothelial Carcinoma, Journal Club - Christopher Wallis & Zachary Klaassen
October 12, 2022
Details
EV-103 Cohort K, Enfortumab Vedotin Monotherapy or in Combination With Pembrolizumab in Previously Untreated Cisplatin-Ineligible Patients With Locally Advanced or Metastatic Urothelial Cancer – Jonathan E. Rosenberg
October 6, 2022
Details
Molecular Subtyping and Neoadjuvant Chemotherapy in Bladder Cancer - Christopher Wallis & Zachary Klaassen
September 27, 2022
Details
Pembrolizumab Alone or Combined With Chemotherapy vs Chemotherapy As First-Line Therapy for Advanced Urothelial Carcinoma in the KEYNOTE-361 Trial Journal Club – Christopher Wallis & Zachary Klaassen
September 27, 2022
Details
CheckMate 274 Trial of Adjuvant Nivolumab vs Placebo in Patients Who Underwent Radical Surgery for High-Risk Muscle-Invasive Urothelial Carcinoma, Journal Club - Christopher Wallis & Zachary Klaassen
September 26, 2022
Details
The Role of Risk-Stratified Neoadjuvant Chemotherapy in Patients with Muscle-Invasive Bladder Cancer Who Are Undergoing Radical Cystectomy - Arlene O. Siefker-Radtke and Shilpa Gupta
August 5, 2022
Details
ATLANTIS Trial Explores Precision Medicine in Urothelial Carcinoma - Robert Jones
June 27, 2022
Details
Overall Response Rate After Immune-Checkpoint Inhibitor Initiation and Post-ICI PFS in Patients With Advanced Urothelial Carcinoma - Dimitrios Makrakis
May 24, 2022
Details
Outcomes Between Patients With and Without Prior Intravesical BCG, Who Received Immune Checkpoint Inhibitors for Advanced Urothelial Carcinoma - Rafee Talukder & Petros Grivas
May 11, 2022
Details
Navigating the Complex Landscape of Adjuvant Trials in Urothelial Carcinoma - Robert Dreicer
May 2, 2022
Details
The Role of ctDNA in Metastatic Urothelial Cancer - Alexander Wyatt
April 19, 2022
Details
Antibody-Drug Conjugates in Advanced Urothelial Cancer: Clinical Perspective - Scott Tagawa
April 14, 2022
Details
Final Analysis of the ATLANTIS Rucaparib Arm - Simon Crabb
May 13, 2022
Details
Practice Changing Publications in Urothelial Carcinoma - Deborah Kaye
April 3, 2022
Details
Treatment Strategies in Advanced Urothelial Carcinoma - Stephen Boorjian
March 29, 2022
Details
The Future of Adjuvant and Neoadjuvant Therapy for Patients with Muscle-Invasive Bladder Cancer - Tracy Rose
March 21, 2022
Details
The Efficacy and Safety of Lenvatinib in Combination with Pembrolizumab in the Treatment of Cisplatin-Ineligible Patients in Advanced Urothelial Carcinoma (LEAP-011) - Yohann Loriot
February 25, 2022
Details
Highlights In Urothelial Carcinoma at GU ASCO 2022 - Guru Sonpavde
February 23, 2022
Details
Sacituzumab Govitecan in Combination with Pembrolizumab in Metastatic Urothelial Cancer - Petros Grivas
February 22, 2022
Details
Clinical Outcomes With Anti-PD(L)1 Immune Checkpoint Inhibitors in Patients With Advanced Urothelial Carcinoma – Dimitrios Makrakis
February 1, 2022
Details
Bladder Cancer Advocacy Network's (BCAN) Young Investigator Award Program - Elizabeth Plimack
January 28, 2022
Details
Biomarkers and Next Generation Sequencing in Advanced Bladder Cancer - Noah Hahn
December 16, 2021
Details
Cisplatin-Related Immunomodulation and Efficacy with Atezolizumab + Cisplatin Versus Carboplatin-Based Chemotherapy in Metastatic Urothelial Cancer - Matthew Galsky
November 4, 2021
Details
Implications for Genetic Testing in Urothelial Cancer - Guru Sonpavde & Maria Carlo
August 17, 2021
Details
Sacituzumab Govitecan in Patients With Metastatic Urothelial Carcinoma, Progressing After Platinum-Based Chemotherapy and Checkpoint Inhibitors: TROPHY-U-01 Journal Club – Christopher Wallis & Zachary Klaassen
July 30, 2021
Details
Neoadjuvant Atezolizumab with Gemcitabine and Cisplatin in Patients with Muscle-Invasive Bladder Cancer - Samuel A. Funt
July 29, 2021
Details
Durability and Long Term Outcome of Enfortumab Vedotin + Pembrolizumab in the EV-103 Study in Cisplatin-Ineligible Locally Advanced or Metastatic Urothelial Carcinoma – Terence W. Friedlander
July 29, 2021
Details
Beyond Clinical Trials: Real-World Success with Trimodality Therapy in Bladder Cancer - Sean Sachdev & Praneet Polineni
June 30, 2021
Details
Updated Results from EV-201 Cohort 2 - Enfortumab Vedotin Is A Potential Non-Platinum Option for Cisplatin-Ineligible Patients Following Anti-PD-1/L1 Treatment - Bradley McGregor
June 10, 2021
Details
Advances in the Treatment of Metastatic Urothelial Cancer - Matthew Galsky
May 24, 2021
Details
Breaking Down the TROPHY-U-01 Trial: How Sacituzumab Govitecan Earned FDA Approval for Advanced Bladder Cancer - Neeraj Agarwal & Petros Grivas
May 14, 2021
Details
Intersection of Biology and Clinical Characteristics Towards Personalized Sequential Treatments for MIBC - Andrea Necchi and Ewan Gibb
May 14, 2021
Details
The Role of Imaging in Neoadjuvant Immunotherapy in Muscle-Invasive Bladder Cancer: A Case Study of PURE-01 - Andrea Necchi & Laura Marandino
May 11, 2021
Details
TROPHY-U-01 Results Lead to Accelerated Approval of Sacituzumab Govitecan (Trodelvy) for Pretreated Metastatic Urothelial Carcinoma - Scott Tagawa
May 1, 2021
Details
Chemoradiation in Urothelial Carcinoma: The Herculean Effort Behind the SWOG 1806 Trial - Petros Grivas
April 29, 2021
Details
Variant Histologies of Bladder Cancer - Petros Grivas
April 29, 2021
Details
Practical Considerations for Administering Avelumab Maintenance in Clinical Practice - Petros Grivas and Neeraj Agarwal
April 23, 2021
Details
Voluntary Withdrawal In The US of Durvalumab and of Atezolizumab in Metastatic Urothelial Carcinoma - Petros Grivas
April 22, 2021
Details
Operationalizing the Use of Avelumab in Clinical Practice, The Phase III JAVELIN Bladder 100 Trial - Brenda Martone
April 13, 2021
Details
Characterization of The Genomic Landscape of Post-Neoadjuvant Chemotherapy in MIBC Patients- Andrew Lenis
January 24, 2021
Details
Metastatic and Muscle-Invasive Bladder Cancer European Association of Urology (EAU) Guidelines - J. Alfred Witjes
December 8, 2020
Details
Molecular Changes Associated with Treatment Response in Muscle-Invasive Bladder Cancer Patients Treated with Cisplatin-Based Chemotherapy - Lars Dyrskjøt
November 12, 2020
Details
Two-year JAVELIN Solid Tumor Data Phase 1 Final Results - Andrea Apolo
November 17, 2020
Details
Comparing Nab-Paclitaxel and Paclitaxel in Platinum-Refractory Bladder Cancer - Srikala Sridhar
November 4, 2020
Details
Implications for Reducing Disparities in Muscle-Invasive Bladder Cancer - Samuel Washington III
November 1, 2020
Details
Guidelines for Advanced Urothelial Carcinoma in First-line Treatment for Patients Ineligible or Unfit for Cisplatin - Michiel S. Van der Heijden
November 1, 2020
Details
Evaluating Treatments in Advanced Urothelial Carcinoma - Guru Sonpavde
October 21, 2020
Details
Association Between Clinical Outcomes and Exploratory Biomarkers in the JAVELIN Bladder 100 Trial, Advanced Urothelial Carcinoma - Srikala Sridhar
October 14, 2020
Details
ESMO 2020: The TROPHY-U-01 Study- Sacituzumab Govitecan for Advanced Urothelial Carcinoma - Petros Grivas
September 29, 2020
Details
ESMO 2020: Combination Therapies in Locally Advanced or Metastatic Urothelial Carcinoma Bladder Cancer - Josh Meeks
September 28, 2020
Details
Current Treatment Approaches in Advanced Urothelial Carcinoma - Shilpa Gupta
September 8, 2020
Details
The Dynamic Advancements in Personalized Treatments for Metastatic Urothelial Cancer - Andrea Apolo
August 24, 2020
Details
Prolonging Overall Survival in Patients with Muscle-Invasive Bladder Cancer - Petros Grivas
July 30, 2020
Details
Treatment Approach: Case Study in Aggressiveness Metastatic Urothelial Carcinoma - Makarand Khochikar
August 10, 2020
Details
Advancements in Treatments for Metastatic Urothelial Carcinoma (mUC) - Petros Grivas
June 29, 2020
Details
JAVELIN Bladder 100: Results of First-line Maintenance Therapy Plus Best Supportive Care Demonstrates Significant Prolonged OS in Advanced Urothelial Cancer - Cora Sternberg
June 28, 2020
Details
Assessing the Potential Cost-Effectiveness of the Addition of Atezolizumab to First-Line Platinum Chemotherapy in Advanced Urothelial Carcinoma - Ali Khaki
June 11, 2020
Details
Progress in Bladder Cancer Research - Bishoy Faltas
June 3, 2020
Details
IMvigor010 Primary Analysis from a Phase III Randomized Study of Adjuvant Atezolizumab versus Observation in High-Risk Muscle-Invasive Urothelial Carcinoma - Thomas Powles & Matthew Galsky
May 31, 2020
Details
JAVELIN Bladder 100: Avelumab for Previously Untreated Locally Advanced or Metastatic Urothelial Carcinoma - Thomas Powles
May 31, 2020
Details
Controversial and Complex Cases in Urothelial Cancer - Srikala Sridhar
May 2, 2020
Details
The Impact of Molecular Subtyping and Immune Infiltration on Pathological Response and Outcome Following Neoadjuvant Pembrolizumab in MIBC - Andrea Necchi
April 28, 2020
Details
The Landscape of Advanced Bladder Cancer: A Review of the Last 30-Years - Cora Sternberg
March 23, 2020
Details
Enfortumab Vedotin for Advanced Urothelial Carcinoma - Jonathan Rosenberg
March 8, 2020
Details
Updates on Bladder Cancer Clinical Trials ASCO GU 2020 - Matthew Galsky
February 26, 2020
Details
Recent Advances in the Treatment of Metastatic Urothelial Cancer - Petros Grivas
February 22, 2020
Details
Treatments in Development for Muscle-invasive Bladder Cancer - Min Yuen Teo
January 15, 2020
Details
Advanced Bladder Cancer Clinic: Are you Ready? - Neal Shore
December 18, 2019
Details
Immunotherapy and Chemotherapy Use in Patients with Metastatic Bladder Cancer - Ronac Mamtani and Ravi Parikh
November 25, 2019
Details
Circulating Tumor DNA in Urothelial Cancer - Interview with Bishoy Faltas
October 16, 2019
Details
Upper Tract Urothelial Carcinoma Has a Luminal-Papillary T-cell Depleted Contexture and Activated FGFR3 Signaling - Bishoy Faltas
October 14, 2019
Details
Fibroblast Growth Factor Receptor 3 Alterations and Response to PD-1/PD-L1 Blockade in Patients with Metastatic Urothelial Cancer - Matt Galsky
September 17, 2019
Details
Antibody Drug Conjugates for the Treatment of Metastatic Urothelial Carcinoma - Petros Grivas
July 8, 2019
Details
Erdafitinib Treatment in Metastatic Urothelial Carcinoma - Petros Grivas
July 25, 2019
Details
Biomarker Testing in Metastatic Urothelial Carcinoma - Petros Grivas
August 5, 2019
Details
The Performance Status and Response to Immune Checkpoint Inhibition in Patients with Advanced Urothelial Carcinoma - Ali Khaki
December 13, 2019
Details
Results from CALGB 90601 in Metastatic Urothelial Carcinoma - Jonathan Rosenberg
July 2, 2019
Details
Novel New Approaches in the Neoadjuvant Disease Setting for Bladder Cancer - Petros Grivas
June 24, 2019
Details
Urinary Diversion after Radical Cystectomy - Morgan Roupret
June 17, 2019
Details
Assessing and Managing Toxicities with Immune Checkpoint Inhibitors - Brenda Martone
June 13, 2019
Details
Erdafitinib in Bladder Cancer - Arjun Balar
May 20, 2019
Details
Implications of Clinical Response Following Neoadjuvant Chemotherapy - Seth Lerner
April 19, 2019
Details
Treating Advanced Bladder Cancer - Petros Grivas
July 5, 2019
Details
Optimizing Treatment Outcomes in Muscle Invasive Bladder Cancer (MIBC) - Wassim Kassouf
July 23, 2019
Details
Bladder Sparing Strategies for Urothelial Cancer - Jason Efstathiou
June 21, 2019
Details
Neoadjuvant Treatment in Muscle Invasive Bladder Cancer- Andrea Necchi
June 3, 2019
Details
Antibody-drug Conjugate (ADC) Sacituzumab Govitecan in Metastatic UroThelial Carcinoma - Scott Tagawa
March 26, 2019
Details
Joshua J. Meeks on SWOG 1806 Study
April 1, 2019
Details
Combination Approaches with Immune-Checkpoint Blockade in Bladder Cancer - Matthew Galsky
February 28, 2019
Details
Immune Checkpoint Inhibitors Trials in Urothelial Cancer: Recent Updates and Future Outlook - Andrea Apolo
February 23, 2019
Details
A Conversation on Immuno-Oncology in Bladder Cancer - Petros Grivas
November 14, 2018
Details
Update on Immunotherapy Advances in Renal and Bladder Cancer - Cora Sternberg
October 29, 2018
Details
Advances in Bladder Cancer Beyond Immunotherapy and Checkpoint Inhibitors - Evan Yu
October 8, 2018
Details
Atezolizumab in Metastatic Urothelial Carcinoma Outside Clinical Trials -Pedro Barata
August 29, 2018
Details
Updates on Health-Related Quality-of-Life (HRQoL) analyses in GU Oncology - Cora Sternberg
July 24, 2018
Details
The State of Advanced Bladder Cancer - New Data from AACR 2018 - Interview with Arjun Balar
May 4, 2018
Details